Lexeo Therapeutics (LXEO) Operating Expenses (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Operating Expenses data on file, last reported at $22.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 33.94% year-over-year to $22.3 million; the trailing twelve-month figure through Mar 2026 stood at $97.8 million (down 15.91% YoY), and the FY2025 full-year result was $109.3 million, up 3.3% from the prior year.
• Operating Expenses fell to $22.3 million in Q1 2026, from $23.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $33.8 million in Q1 2025 to a low of $14.0 million in Q2 2023.
• A 5-year average of $22.6 million and a median of $22.3 million in 2026 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 82.86% in 2024 and tumbled 33.94% in 2026, its largest moves.
• Tracing LXEO's Operating Expenses over 5 years: stood at $15.2 million in 2022, then fell by 1.47% to $15.0 million in 2023, then surged by 82.86% to $27.4 million in 2024, then dropped by 15.58% to $23.1 million in 2025, then fell by 3.39% to $22.3 million in 2026.
• Business Quant data shows LXEO's Operating Expenses at $22.3 million in Q1 2026, $23.1 million in Q4 2025, and $21.6 million in Q3 2025.